- Management of the Patient With CLL in the Era of COVID-19
- Active cancer treatment
- Risks in patients with cancer and COVID-19
- Treatment-related risks
- CLL Therapies With Potential to Treat Patients With COVID-19
- BTK inhibitors
- PI3K inhibitors
- Ask the Expert: Question and Answer Session With Faculty
- Faculty will address questions submitted in advance of the program as well as those posed during the live Webinar
John Pagel, MD, PhD
Chief of Hematologic Malignancies
Swedish Cancer Institute
The goal of this activity is to provide a comprehensive, agile, and highly accessible educational resource to improve oncology healthcare professionals’ competence in providing optimal care for patients with CLL during the COVID-19 pandemic and increase knowledge about ongoing research into blunting the production of inflammatory cytokines in COVID-19 Infection.
This program is intended for physicians who care for patients with respiratory complications associated with COVID-19 infection and/or CLL.
Upon completion of this activity, participants should be able to:
- Apply best practices for clinic/center preparedness to limit infection risk
- Provide appropriate care for patients with CLL in the era of COVID-19
- Select or modify treatment for newly diagnosed and relapsed/refractory CLL based on the available clinical data, guidelines, and expert recommendations to reduce office visits and maintain efficacy
- Integrate telemedicine for routine follow-up visits, as appropriate
- Manage adverse events associated with treatment approaches for CLL to ensure treatment compliance as well as improved clinical outcomes and quality of life
- Provide counsel to patients and caregivers based on best practices for infection control
- Describe the relevance of inflammatory cytokines in respiratory complications associated with COVID-19
- Assess available evidence on the safety and efficacy of immunomodulatory agents that may ameliorate the “cytokine storm” associated with severe disease
- Refer eligible patients to clinical trials of agents that target inflammatory cytokine release
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.